News and Announcements
Universal Biosensors (ASX: UBI) Annual Update 2015; Share Price up 159% & Revenues up 160%
- Published December 16, 2015 3:47PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Universal Biosensors has seen its share price more than double over the year, up from 17.6c on January 5 to 44.5c on December 14 – an increase of 159%.
The company’s financial performance has also been strong, with total revenues in the first half up 160% on the prior corresponding period and quarterly service fees from industry partner LifeScan up 153%. Third quarter results showed continuing strong revenue growth, up 187% on pcp and nett increase in cash of $1M.
Development of new point-of-care coagulation testing systems continue to progress and a new board member, Judith Smith, was appointed.
ABOUT UNIVERSAL BIOSENSORS
Universal Biosensors is a specialist medical diagnostics company developing and manufacturing test systems for point-of-care (POC) medical professionals and home use. UBI’s core technology is a disposable, multi-layer test strip, which uses its proprietary electrochemical sensor to rapidly and accurately measure biomarkers in the blood. The company already has developed products in collaboration with LifeScan (Johnson & Johnson) and Siemens Healthcare.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
